Double blinded study of high frequency repetitive transcranial magnetic stimulator for Parkinson's disease. (rTMS treatment study of Parkinson's disease)

Nihon Kohden Corporation0 个研究点开始时间: 待定最近更新: 2019年3月18日

试验速览

阶段: 不适用
状态: 已完成
发起方: Nihon Kohden Corporation
主要终点: -

研究概览入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

入排标准

年龄范围: 20age old over 至 No limit（—）

入选标准

•Eligible patients are expected to meet all of the following criteria:
•(1) PD patients diagnosed as Idiopathic PD based on the criteria of UK Parkinson's Disease Society brain bank
•(2) PD patients whose symptoms are not considerably improved with L-dopa and/or dopamine agonist treatments, and also are at stage 2 to 4 in the modified Hoehn-Yahr Scale
•(3) Patients who have been receiving a stable dosage of L-dopa and/or dopamine agonist at regular intervals for 4 weeks before rTMS treatment
•(4) Patients who have been receiving a stable dosage of anticholinergic drugs, selegiline, entacapone, amantadine hydrochloride, droxidopa, zonisamide or istradefylline at regular intervals for 4 weeks before rTMS treatment
•(5) Patients 20 years and older at time of providing informed consent
•(6) In-patients or out-patients who can come to the hospitals where the study is conducted
•(7) Patients who have voluntarily provided written consent for participation in this study, based on complete understanding our full explanation

排除标准

•Patients meeting any of the following criteria are ineligible for this study:
•(1) Patients exhibiting severe psychiatric symptoms such as severe hallucinations, delusion, confusion, abnormal behavior and so on, within 6 months (26 weeks) before the initiation of rTMS treatment
•(2) Patients with drug or alcohol addiction (by ICD10 classification)
•(3) Patients with less than a 24 score in mini-mental state examination at a screening
•(4) Patients with less than a 11 score in UPDRS Part III at a screening
•(5) Patients having a history of receiving surgical treatments (such as deep brain stimulation)
•(6) Patients having taken medication listed below within 4 weeks of the initiation of rTMS treatment
•+ dopamine receptor antagonistic antipsychotics (e.g. phenothiazines, butyrophenones, benzamides)
•+ dopamine receptor antagonistic cardiovascular drugs (e.g. reserpine)
•(7) Patients taking medication listed below currently or having taken it within 1 week of the initiation of rTMS treatment.
•+ dopamine receptor antagonistic gastrointestinal drugs (e.g. metoclopramide and sulpiride, except for domperidone)
•(8) Patients who have previously received rTMS treatment
•(9) Patients with metal implants (e.g. clips, metals, and cochlear implant) in the head (except for oral implants)
•(10) Patients having a cardiac pacemaker, implantable cardioverter defibrillators (ICD), vagal nerve stimulator or implantable drug infusion pump
•(11) Patients with a large cerebral infarction, cerebral trauma, brain tumor, or epilepsy
•(12) Patients having a malignant tumor, severe hepatic, renal, hematologic, respiratory, gastrointestinal or cardiovascular disease or metabolic or electrolyte imbalance. (Patients having a history of malignant tumors but being free of relapse for more than 5 years are allowed to be included. Severity criteria are based on grade 4 in Common Terminology Criteria for Adverse Events (CTCAE) v4.0.)
•(13) Patients in whom no motor evoked potentials were elicited from the tibialis anterior muscle by TMS at the maximum stimulator output
•(14) Patients who participated in other trials within 12 weeks before the date of providing informed consent for this study
•(15) Pregnant patients or patients having a possibility of pregnancy. Patients who are breast feeding or attempting to become pregnant.
•(16) Patients who were judged as ineligible by the principle investigator or subinvestigator

结局指标

主要结局

Changes in UPDRS Part III (motor symptoms) total score at drug-on stage from the baseline score.

次要结局

Time course of modified Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (Part I to IV, total)
Time course of self-assessed daily activity (Visual analog scale)
Time course of averaged duration of off period in a day
Changes in dropouts due to increasing or addition of anti-Parkinsonian drugs as a result of worsening of motor symptoms

研究者

发起方

Nihon Kohden Corporation

相似试验

已完成

不适用

Comparison of two methods of pain relief in pediatric laparoscopic surgeries

CTRI/2020/02/023157RAINBOW CHILDRENS HOSPITA100

尚未招募

Unknown

Comparing two methods for relief of labour pain-giving drug continously via a catheter placed in epidural space versus puncturing the dura with a smaller spinal needle and giving the drug continously via epidural catheter.

CTRI/2023/10/058848Riya Varghese

招募中

Unknown

COMPARING THE EFFECTS OF TWO PAIN RELIEVING MEDICINES ON CHILDREN UNDERGOING THROAT SURGERIES

CTRI/2020/03/023680OT APPLICABLE

进行中（未招募）

1 期

An intervention study of the effects of a low dose and high dose hydrocortisone replacement therapy on brain functions, quality of life, risk factors for cardiovascular diseases and sensitivity in patients with adrenal insufficiency due to a previous pituitary tumor.

EUCTR2011-000864-82-NLniversity Medical Center Groningen63

尚未招募

4 期

Pain relief injections by using ultrasound machine to nerve groups in neck for thyroid removal surgeries for continuous pain relief even after surgery.

CTRI/2024/06/069242Vijayanagar institute of medical sciences